Clinical experience with BIAsp 30: Results from the Bangladesh cohort of the global A1chieve study

Authors

  • ZA Latif Department of Endocrinology, BIRDEM Hospital, Dhaka
  • MF Pathan Department of Endocrinology, BIRDEM Hospital, Dhaka
  • MA Mannan Department of Endocrinology, Dhaka Medical College & Hospital (DMCH), Dhaka
  • MNT Siddiqui Department of Endocrinology, Mymensingh Medical College & Hospital (MMCH), Mymensingh
  • SM Ashrafuzzaman Department of Endocrinology, BIRDEM Hospital, Dhaka
  • MM Rahman Medical Services, Novo Nordisk Pharma (Pvt.) Ltd
  • MJ Sobhan Medical Services, Novo Nordisk Pharma (Pvt.) Ltd

DOI:

https://doi.org/10.3329/bmrcb.v39i3.20307

Keywords:

A1chiev study, BIAsp 30

Abstract

The aim of A1chieve was to remedy the deficit of data on the efficacy and safety of insulin analogues in routine clinical care in less well-resourced developed countries. To present results from the Bangladesh cohort of the A1chieve study receiving BIAsp 30 ± oral anti diabetic drugs. A1chieve was a 6-month, observational study of 66,726 people with type 2 diabetes, started on insulin detemir, insulin aspart or biphasic insulin aspart (BIAsp 30) in 28 countries across four continents. A total of 1,093 subjects were recruited from 49 sites in Bangladesh and 580 subjects initiated on BIAsp 30 were studied. In the entire cohort, treatment with BIAsp 30 for 24 weeks significantly reduced mean HbA1c (2.8%, p<0.001), fasting plasma glucose (4.0mmol/L, p<0.001) and post prandial plasma glucose (6.6mmol/L, p<0.001) levels from baseline. The rate of overall hypoglycaemic events in the entire cohort also reduced significantly at 24 weeks (1.86 to 0.02 events/person year, p<0.0001). BIAsp 30 can be considered as a safe and effective option for initiating as well as intensifying insulin therapy for type 2 diabetes.

DOI: http://dx.doi.org/10.3329/bmrcb.v39i3.20307

Bangladesh Med Res Counc Bull 2013; 39: 93-98

Downloads

Download data is not yet available.
Abstract
128
PDF
114

Downloads

Published

2014-09-04

How to Cite

Latif, Z., Pathan, M., Mannan, M., Siddiqui, M., Ashrafuzzaman, S., Rahman, M., & Sobhan, M. (2014). Clinical experience with BIAsp 30: Results from the Bangladesh cohort of the global A1chieve study. Bangladesh Medical Research Council Bulletin, 39(3), 93–98. https://doi.org/10.3329/bmrcb.v39i3.20307

Issue

Vol. 39 No. 3 (2013)

Section

Research Papers

License

Authors who publish with this journal agree to the following terms.

Authors retain copyright and grant the journal right of first publication.

Creative Commons Licence
Articles in the Bangladesh Medical Research Council Bulletin are licensed under a Creative Commons Attribution 4.0 International License (CC-BY) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).